Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0F8CM
|
||||
| Former ID |
DAP001025
|
||||
| Drug Name |
Pentosan Polysulfate
|
||||
| Synonyms |
Elmiron; Pentosan sulfuric polyester; Polypentose sulfate; Elmiron (TN); Xylan,hydrogen sulfate; [(2R,3R,4S,5R)-2-hydroxy-5-[(2S,3R,4S,5R)-5-hydroxy-3,4-disulfooxyoxan-2-yl]oxy-3-sulfooxyoxan-4-yl] hydrogen sulfate
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Interstitial cystitis; Painful bladder syndrome [ICD9: 595.1,338,780; ICD10:N30.1, G89, R52] | Approved | [538539] | ||
| Therapeutic Class |
Anticoagulants
|
||||
| Company |
Ortho-McNeil Pharmaceutical
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C10H18O21S4
|
||||
| Canonical SMILES |
C1C(C(C(C(O1)OC2COC(C(C2OS(=O)(=O)O)OS(=O)(=O)O)O)OS(=O<br />)(=O)O)OS(=O)(=O)O)O
|
||||
| InChI |
1S/C10H18O21S4/c11-3-1-26-10(8(31-35(22,23)24)5(3)28-32(13,14)15)27-4-2-25-9(12)7(30-34(19,20)21)6(4)29-33(16,17)18/h3-12H,1-2H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)/t3-,4-,5+,6+,7-,8-,9-,10+/m1/s1
|
||||
| InChIKey |
FCCNSUIJIOOXEZ-SJYYZXOBSA-N
|
||||
| CAS Number |
CAS 37300-21-3
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| SuperDrug ATC ID |
B01AX06
|
||||
| SuperDrug CAS ID |
cas=140207938
|
||||
| Target and Pathway | |||||
| Target(s) | Fibroblast growth factor-4 | Target Info | Modulator | [556264] | |
| PANTHER Pathway | FGF signaling pathway | ||||
| Pathway Interaction Database | Regulation of nuclear beta catenin signaling and target gene transcription | ||||
| FGF signaling pathway | |||||
| Reactome | PI3K Cascade | ||||
| PIP3 activates AKT signaling | |||||
| FGFR4 ligand binding and activation | |||||
| FGFR3c ligand binding and activation | |||||
| FGFR2c ligand binding and activation | |||||
| FGFR3 mutant receptor activation | |||||
| Activated point mutants of FGFR2 | |||||
| Constitutive Signaling by Aberrant PI3K in Cancer | |||||
| Phospholipase C-mediated cascade: FGFR1 | |||||
| Phospholipase C-mediated cascade | |||||
| Phospholipase C-mediated cascade | |||||
| Phospholipase C-mediated cascade | |||||
| SHC-mediated cascade:FGFR1 | |||||
| PI-3K cascade:FGFR1 | |||||
| FRS-mediated FGFR1 signaling | |||||
| PI-3K cascade:FGFR2 | |||||
| SHC-mediated cascade:FGFR2 | |||||
| FRS-mediated FGFR2 signaling | |||||
| SHC-mediated cascade:FGFR3 | |||||
| FRS-mediated FGFR3 signaling | |||||
| PI-3K cascade:FGFR3 | |||||
| FRS-mediated FGFR4 signaling | |||||
| SHC-mediated cascade:FGFR4 | |||||
| PI-3K cascade:FGFR4 | |||||
| Negative regulation of FGFR1 signaling | |||||
| Negative regulation of FGFR2 signaling | |||||
| Negative regulation of FGFR3 signaling | |||||
| Negative regulation of FGFR4 signaling | |||||
| RAF/MAP kinase cascade | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.